Pyxis Oncology Grants Stock Options to Newly Hired Employees Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology granted stock options to purchase 382,518 shares of common stock to seven newly hired employees. The awards were made under the Pyxis Oncology 2022 Inducement Plan and were granted as an inducement to the new employees entering employment with the company. The stock options vest over four years or in full on December 31, 2025, subject to continuous service with the company.

Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company specializing in antibody-drug conjugate (ADC) therapeutics, has announced the grant of stock options to seven newly hired employees under its 2022 Inducement Plan. The total number of shares granted is 382,518, with 261,268 shares vesting over four years and 121,250 shares vesting on December 31, 2025, subject to continuous service with the company Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)^[1].

The stock options have a ten-year term and an exercise price of $2.22 per share, matching the closing stock price of Pyxis Oncology on September 30, 2025. The grants are in compliance with Nasdaq Listing Rule 5635(c)(4), which requires companies to report such inducements Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)^[1].

The vesting schedule for the 261,268 shares involves 25% vesting on the first anniversary of the vesting commencement date for each employee, with the remaining shares vesting monthly over the 36-month period thereafter. The 121,250 shares will vest in full on December 31, 2025, provided the recipient maintains continuous service with the company Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)^[1].

Pyxis Oncology is focused on developing next-generation ADC therapeutics for difficult-to-treat cancers. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is currently being evaluated in Phase 1 clinical studies for various solid tumors, with a specific focus on recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The company has also initiated a Phase 1/2 combination study of MICVO with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)^[1].